Pfizer Inc PFE shares are trading lower on Tuesday after the company and its COVID-19 vaccine partner paused an updated-shot ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer and ...

Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year. Even if ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

Pfizer Inc. (NYSE: PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions ...

Pfizer is one of the largest pharmaceutical companies on the planet. It has a proven track record of finding, developing, and commercializing new drugs. The recent price advance is worth paying ...

Pfizer (NYSE: PFE) is one of the world's largest pharmaceutical companies. It has a long history of innovation and success. Add in a lofty 6.6% dividend yield, and dividend investors are likely to ...